TrialBMC psychiatry2018

Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.

Vasiliki Mamakou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.